<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2216-0973</journal-id>
<journal-title><![CDATA[Revista Cuidarte]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cuid]]></abbrev-journal-title>
<issn>2216-0973</issn>
<publisher>
<publisher-name><![CDATA[Programa de Enfermería, Facultad de Ciencias de la Salud, Universidad de Santander UDES]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2216-09732022000300018</article-id>
<article-id pub-id-type="doi">10.15649/cuidarte.2657</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Seroprevalencia de SARS-CoV-2 y factores asociados en migrantes con vocación de permanencia, Bucaramanga, Colombia]]></article-title>
<article-title xml:lang="en"><![CDATA[SARS-CoV-2 seroprevalence and associated factors among migrants with a vocation for permanence, Bucaramanga, Colombia]]></article-title>
<article-title xml:lang=""><![CDATA[Soroprevalencia de SARS-CoV-2 e fatores associados em migrantes com vocaao de permanencia, Bucaramanga, Colombia.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Vega]]></surname>
<given-names><![CDATA[Ruth Aralí]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Bolívar-Grimaldos]]></surname>
<given-names><![CDATA[Alix]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rincón-Orozco]]></surname>
<given-names><![CDATA[Bladimiro]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Santander  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Laboratorios Bolívar  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Industrial de Santander  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2022</year>
</pub-date>
<volume>13</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S2216-09732022000300018&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S2216-09732022000300018&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S2216-09732022000300018&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Existen pocos reportes que evalúen la seroprevalencia contra SARS-CoV-2 en población migrante en el mundo. Estos estudios ayudan a conocer la exposición al virus en las poblaciones para implementar acciones que reduzcan el impacto de la infección por SARS-CoV-2.  Objetivo: Determinar la seroprevalencia contra SARS CoV-2 en migrantes con vocación de permanencia en Bucaramanga, e identificar factores asociados a la infección previa por SARS-CoV-2.  Materiales y métodos: Estudio de corte transversal analítico con muestreo consecutivo. Se incluyeron migrantes adultos en Bucaramanga durante febrero/2021. Se realizaron encuestas e inmunoensayos de quimioluminiscencia para IgM e IgG contra SARS-CoV-2 en suero. Se calcularon razones de prevalencia (RP) con regresión log-binomial.  Resultados: Se incluyeron 462 participantes. La seroprevalencia de IgM fue 11,7% (IC95% 9,1-14,9), de IgG fue 32,9% (IC95% 28,8 37,3) y de IgM o IgG fue 36,1% (IC95% 31,9-40,6). Exposición a un caso confirmado (RP:1,54; IC95%1,04-2,29) o sospechoso (RP:1,56; IC95%1,13-2,16) de COVID-19, seis o más convivientes (RP:1,52; IC95%1,05-2,20), estancia en Colombia &gt;2 años (RP:1,43; IC95%1,11-1,92) y presencia de síntomas (RP:1,62; IC95%1,26 - 2,10) se asociaron con mayor seroprevalencia de IgG.  Discusión: En Bucaramanga, la seroprevalencia en migrantes fue similar a la de migrantes en Kuwait, pero menor que en Paris y Singapur.  Conclusión: En migrantes con vocación de permanencia la seroprevalencia contra SARS-CoV-2 fue similar a la reportada en residentes de Bucaramanga. El contacto con casos sospechosos/confirmados de COVID-19 y las condiciones de hacinamiento fueron algunos de los factores asociados a la seroprevalencia.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: There are few reports assessing anti-SARS-CoV-2 seroprevalence in the migrant population in the world. These studies help to understand the exposure of populations to the virus to take actions to reduce the impact of SARS-CoV-2 infection.  Objective: To determine the anti-SARS-CoV-2 seroprevalence in migrants with a vocation for permanence in Bucaramanga and to identify factors associated with previous SARS-CoV-2 infection.  Methods: Analytical cross-sectional study using consecutive sampling, which included adult migrants in Bucaramanga in February 2021. Surveys were conducted, and chemiluminescent immunoassays were performed to detect IgM and IgG antibodies to SARS-CoV-2 in serum samples. Prevalence ratios (PR) were estimated using a log-binomial regression model.  Results: The study enrolled 462 participants. IgM seroprevalence was 11.7% (95% CI 9.1-14.9), IgG seroprevalence was 32.9% (95% CI 28.8-37.3), and IgM or IgG seroprevalence was 36.1% (95% CI 31.9-40.6). Contact with a confirmed case of COVID-19 (PR:1.54; 95% CI 1.04-2.29) or suspected case (PR:1.56; 95% CI 1.13-2.16); living with six or more people (PR: 1.52; 95% CI 1.05-2.20); stay in Colombia &gt; 2 years (PR:1.43; 95% CI 1.11-1.92), and presence of symptoms (PR:1.62; 95%CI 1.26-2.10) were some factors associated with higher IgG seroprevalence.  Discussion: In Bucaramanga, SARS-CoV-2 seroprevalence among migrants was similar to the seroprevalences of migrants in Kuwait but lower than migrants in Paris and Singapore.  Conclusions: The anti-SARS-CoV-2 seroprevalence among migrants with a vocation for permanence was similar to that reported among residents of Bucaramanga. Contact with suspected or confirmed COVID-19 cases and crowded conditions were some of the factors associated with seroprevalence.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo  Introdujo: Existem poucos relatos que avaliam a soroprevalencia contra SARS-CoV-2 na populagáo migrante no mundo. Esses estudos ajudam a conhecer a exposigáo ao virus nas populates para implementar agóes que reduzam o impacto da infecgáo por SARS-CoV-2.  Objetivo: Determinar a soroprevalencia contra SARS CoV-2 em migrantes que pretendem permanecer em Bucaramanga e identificar fatores associados a infecgáo anterior por SARS-CoV-2.  Métodos: Estudo analítico transversal com amostragem consecutiva. Foram incluídos migrantes adultos em Bucaramanga durante fevereiro/2021. Foram realizados levantamentos e imunoensaios de quimioluminescencia para IgM e IgG contra SARS-CoV-2 no soro. As razóes de prevalencia (RP) foram calculadas com regressáo log-binomial.  Resultados: foram incluídos 462 participantes. A soroprevalencia de IgM foi de 11,7% (IC 95% 9,1-14,9), de IgG foi de 32,9% (IC 95% 28,8 37,3) e de IgM ou IgG foi de 36,1% (IC95% 31,9-40,6). Exposigáo a um caso confirmado (RP: 1,54; IC 95% 1,04-2,29) ou caso suspeito (RP: 1,56; IC 95% 1,13-2,16) de COVID-19, seis ou mais coabitantes (RP: 1,52; IC 95% 1,05 -2,20), permanencia na Colombia &gt;2 anos (Rp: 1,43; IC 95% 1,11-1,92) e presenga de sintomas (RP: 1,62; IC95%1,26 - 2,10) foram associados a maior soroprevalencia de IgG.  Discussao: Em Bucaramanga, a soroprevalencia em migrantes foi semelhante a de migrantes no Kuwait, mas menor do que em Paris e Cingapura.  Conclusao: Em migrantes com vocagáo de permanencia, a soroprevalencia contra SARS-CoV-2 foi semelhante a relatada em residentes de Bucaramanga. O contato com casos suspeitos/confirmados de COVID-19 e as condigóes de superlotagáo foram alguns dos fatores associados a soroprevalencia.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="es"><![CDATA[Estudios Seroepidemiológicos]]></kwd>
<kwd lng="es"><![CDATA[Migrantes.]]></kwd>
<kwd lng="en"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="en"><![CDATA[Seroepidemiologic Studies]]></kwd>
<kwd lng="en"><![CDATA[Transients and Migrants.]]></kwd>
<kwd lng="pt"><![CDATA[SARS-CoV-2]]></kwd>
<kwd lng="pt"><![CDATA[Estudos Soroepidemiológicos, Migrantes.]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<collab>Coronaviridae Study Group of the International Committee on Taxonomy of Viruses</collab>
<article-title xml:lang=""><![CDATA[The species Severe acute respiratory syndrome-related coronavirus classifying 2019-nCoV and naming it SARS-CoV-2]]></article-title>
<source><![CDATA[Nat Microbiol]]></source>
<year>2020</year>
<volume>5</volume>
<page-range>536-44</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<collab>WHO</collab>
<source><![CDATA[(COVID-19). World Health Organization]]></source>
<year>2021</year>
<publisher-name><![CDATA[WHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>Minsalud, Cluster Salud Colombia, OPS</collab>
<source><![CDATA[Casos de COVID-19 de población migrante y refugiados venezolana en Colombia, corte 30 de Junio, 2020]]></source>
<year>2020</year>
<publisher-name><![CDATA[PAHO]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Orcutt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Patel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Burns]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hiam]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Aldridge]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Devakumar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Global call to action for inclusion of migrants and refugees in the COVID-19 response]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
<volume>395</volume>
<page-range>1482-3</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hargreaves]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Zenner]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Wickramage]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Deal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hayward]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Targeting COVID-19 interventions towards migrants in humanitarian settings]]></article-title>
<source><![CDATA[Lancet Infect Dis]]></source>
<year>2020</year>
<volume>20</volume>
<page-range>645-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Daniels]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Venezuelan migrants &#8220;struggling to survive&#8221; amid COVID-19]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>2020</year>
<volume>395</volume>
<page-range>1023</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>Organización de los Estados Americanos</collab>
<source><![CDATA[Informe de situación diciembre 2020. Crisis de migrantes y refugiados venezolanos]]></source>
<year>2020</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alali]]></surname>
<given-names><![CDATA[WQ]]></given-names>
</name>
<name>
<surname><![CDATA[Bastaki]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Longenecker]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Aljunid]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[AlSeaidan]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chehadeh]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seroprevalence of SARS-CoV-2 in migrant workers in Kuwait]]></article-title>
<source><![CDATA[J Travel Med]]></source>
<year>2021</year>
<volume>28</volume>
<page-range>223</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Roederer]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mollo]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Vincent]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Nikolay]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Llosa]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Nesbitt]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seroprevalence and risk factors of exposure to COVID-19 in homeless people in Paris, France a cross-sectional study]]></article-title>
<source><![CDATA[Lancet Public Health]]></source>
<year>2021</year>
<volume>6</volume>
<page-range>202-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<name>
<surname><![CDATA[Dan]]></surname>
<given-names><![CDATA[YY]]></given-names>
</name>
<name>
<surname><![CDATA[Aw]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cook]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prevalence and Outcomes of SARS-CoV-2 Infection Among Migrant Workers in Singapore]]></article-title>
<source><![CDATA[JAMA]]></source>
<year>2021</year>
<volume>325</volume>
<page-range>584-5</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Padoan]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cosma]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sciacovelli]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Faggian]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Plebani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analytical performances of a chemiluminescence immunoassay for SARS-CoV-2 IgM/IgG and antibody kinetics]]></article-title>
<source><![CDATA[Clin Chem Lab Med]]></source>
<year>2020</year>
<volume>58</volume>
<page-range>1081-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deeks]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dinnes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Takwoingi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Davenport]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Spijker]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Taylor-Phillips]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibody tests for identification of current and past infection with SARS-CoV-2]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2020</year>
<volume>6</volume>
<page-range>13652</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montesinos]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Gruson]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kabamba]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Dahma]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evaluation of two automated and three rapid lateral flow immunoassays for the detection of anti-SARS-CoV-2 antibodies]]></article-title>
<collab>Van den Wijngaert S.Reza S</collab>
<source><![CDATA[J Clin Virol]]></source>
<year>2020</year>
<volume>128</volume>
<page-range>104413</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdivia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Latorre]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Francés-Gómez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gozalbo-Rovira]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inference of SARS-CoV-2 spike-binding neutralizing antibody titers in sera from hospitalized COVID-19 patients by using commercial enzyme and chemiluminescent immunoassays]]></article-title>
<source><![CDATA[Eur J Clin Microbiol Infect Dis]]></source>
<year>2021</year>
<volume>40</volume>
<page-range>485-94</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sempos]]></surname>
<given-names><![CDATA[CT]]></given-names>
</name>
<name>
<surname><![CDATA[Tian]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit Error]]></article-title>
<source><![CDATA[Am J Epidemiol]]></source>
<year>2021</year>
<volume>190</volume>
<page-range>109-15</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez-Vega]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bolívar-Grimaldos]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rincon]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[Seroprevalencia de SARS-CoV-2 y factores asociados en migrantes con vocación de permanencia, Bucaramanga, Colombia]]></source>
<year>2022</year>
<publisher-name><![CDATA[Mendeley Data]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valdivia]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Huntley]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Alcaraz]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Albert]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Caveats in interpreting SARS-CoV-2 IgM+ /IgG- antibody profile in asymptomatic health care workers]]></article-title>
<collab>Solano de la Asunción C</collab>
<source><![CDATA[J Med Virol]]></source>
<year>2021</year>
<volume>93</volume>
<page-range>634-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clapham]]></surname>
<given-names><![CDATA[HE]]></given-names>
</name>
<name>
<surname><![CDATA[Chia]]></surname>
<given-names><![CDATA[WN]]></given-names>
</name>
<name>
<surname><![CDATA[Tan]]></surname>
<given-names><![CDATA[LWL]]></given-names>
</name>
<name>
<surname><![CDATA[Kumar]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Lim]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Shankar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Contrasting SARS-CoV-2 epidemics in Singapore cohort studies in migrant workers and the general population]]></article-title>
<source><![CDATA[Int J Infect Dis]]></source>
<year>2022</year>
<volume>115</volume>
<page-range>72-8</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hasan]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Thach]]></surname>
<given-names><![CDATA[PN]]></given-names>
</name>
<name>
<surname><![CDATA[Anh]]></surname>
<given-names><![CDATA[NT]]></given-names>
</name>
<name>
<surname><![CDATA[Hien]]></surname>
<given-names><![CDATA[LTT]]></given-names>
</name>
<name>
<surname><![CDATA[An]]></surname>
<given-names><![CDATA[NTM]]></given-names>
</name>
<name>
<surname><![CDATA[Thuy]]></surname>
<given-names><![CDATA[DT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prevalence of SARS-CoV-2 antibodies in quarantine workers and high-risk communities in Vietnam]]></article-title>
<source><![CDATA[IJID Reg]]></source>
<year>2022</year>
<volume>2</volume>
<page-range>137-40</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Warszawski]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Franck]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Rahib]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Lydié]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Gosselin]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Trends in social exposure to SARS-Cov-2 in France. Evidence from the national socio-epidemiological cohort-EPICOV]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2022</year>
<volume>25</volume>
<numero>17</numero>
<issue>17</issue>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al-Abri]]></surname>
<given-names><![CDATA[SS]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Wahaibi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Kindi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kurup]]></surname>
<given-names><![CDATA[PJ]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Maqbali]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Mayahi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seroprevalence of SARS-CoV-2 antibodies in the general population of Oman results from four successive nationwide sero-epidemiological surveys]]></article-title>
<source><![CDATA[Int J Infect Dis]]></source>
<year>2021</year>
<volume>112</volume>
<page-range>269-77</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<collab>Instituto Nacional de Salud &amp; Grupo Colaborativo Estudio País</collab>
<source><![CDATA[Seroprevalencia de SARS- CoV-2 durante la epidemia en Colombia: Estudio país (Reporte Preliminar No 5: Resultados globales Leticia, Barranquilla, Medellín, Bucaramanga, Cúcuta, Villavicencio, Cali, Bogotá, Ipiales, Guapí)]]></source>
<year>2021</year>
<publisher-loc><![CDATA[Bogotá ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Nacional de Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Colmenares-Mejía]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
<name>
<surname><![CDATA[Serrano-Díaz]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Quintero-Lesmes]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Meneses]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar Acosta]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Idrovo]]></surname>
<given-names><![CDATA[ÁJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Seroprevalence of SARS-CoV-2 Infection among Occupational Groups from the Bucaramanga Metropolitan Area, Colombia]]></article-title>
<source><![CDATA[Int J Environ Res Public Health]]></source>
<year>2021</year>
<volume>15</volume>
<numero>18</numero>
<issue>18</issue>
<page-range>4172</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vengesai]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Midzi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kasambala]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mutandadzi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mduluza-Jokonya]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Rusakaniko]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic and meta-analysis review on the diagnostic accuracy of antibodies in the serological diagnosis of COVID-19]]></article-title>
<source><![CDATA[SystRev]]></source>
<year>2021</year>
<volume>26</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>155</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
